



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASTELIC *et al.*

Appl. No.: 10/814,634

Filed: April 1, 2004

For: **Assay for Identifying Compounds
Which Affect Stability of mRNA**

Confirmation No.: 8704

Art Unit: 1636

Examiner: *(To be assigned)*

Atty Docket: 1556.0290001/RWE/JKM

Preliminary Amendment Under 37 C.F.R. § 1.115

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution in the above identified matter, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made; and
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under

37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

In the specification, after the Abstract of the Disclosure at page 57 and before the drawings, please delete the current sequence listing and substitute therefore the Substitute Sequence Listing (pages 1-8) that is appended hereto.